This inventor holds 2 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignee: Novartis Ag. Active years: 2017-2018.
Company Filing History:
Years Active: 2017-2018
Title: Annika Schmid: Innovator in Cardiovascular Treatment
Introduction
Annika Schmid is a prominent inventor based in Neuried, Germany. She has made significant contributions to the field of medicine, particularly in the treatment of cardiovascular disorders. With a total of 2 patents, her work focuses on innovative therapeutic approaches that leverage monoclonal antibodies.
Latest Patents
Annika's latest patents include groundbreaking inventions related to methods of treating cardiovascular disorders with lectin-like oxidized LDL receptor 1 antibodies. The first patent describes monoclonal antibodies that bind to human lectin-like oxidized LDL receptor 1 (LOX-1), along with pharmaceutical compositions and treatment methods. The second patent also pertains to lectin-like oxidized LDL receptor 1 antibodies and their applications in treatment, showcasing her dedication to advancing medical science.
Career Highlights
Throughout her career, Annika has been associated with Novartis AG, a leading global healthcare company. Her work at Novartis has allowed her to collaborate with other experts in the field and contribute to significant advancements in cardiovascular therapies.
Collaborations
Some of her notable coworkers include Kurt Alex Heldwein and Jennifer Brogdon, who have worked alongside her in various research initiatives. Their combined expertise has fostered a collaborative environment that enhances the development of innovative treatments.
Conclusion
Annika Schmid's contributions to the field of cardiovascular treatment through her patents and collaborations highlight her role as a leading inventor. Her work continues to pave the way for new therapeutic options that can improve patient outcomes.